ANI PHARMACEUTICALS INC (ANIP) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions and 2 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $2.0M sold). Latest close $71.47 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 13, 2026 · Congress to Nov 16, 2026.
Rubric Capital Management — 1 tracked fund hold ANIP. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 10 sales ($2.0M). Insider trading
No closely related stocks by co-holding for this stock. Browse all stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Rubric Capital Management | 0.20% | 258,131 | NEW Q3 filed Nov 16 |
| Polen Capital Management | — | — | EXITED |
| Deep Track Capital | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -15.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 304 of 8,857 filers |
| Long-only filers among them | 303 |
| Change vs 2026 Q1 | +32 net · 291 entered · 259 exited |
| Shares reported, all filers | 22,898,210 |
| Reported value, all filers | $1.9B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $883.4M |
| Net income · FY2025 | $78.3M |
| Total assets · FY2025 | $1.4B |
| Shares outstanding | 22,491,281 |
| Market cap (at latest close) | $1.6B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Dec 31, 2025.
| Shares short · Oct 15, 2026 | 3,472,078 |
| Share of shares outstanding | 15.44% |
| Days to cover | 10.10 |
Shares short at recent settlements — Jul 31, 2026: 2.3M · Aug 14, 2026: 3.4M · Aug 31, 2026: 3.4M · Sep 15, 2026: 2.5M · Sep 30, 2026: 3.5M · Oct 15, 2026: 3.5M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 10 sales by 4 insiders ($2.0M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $70.80 | $35.4K | SEC filing |
| Oct 29, 2026 | CAREY STEPHEN P. | SVP & CFO | Sell | 2,850 | $72.87 | $207.7K | SEC filing |
| Oct 15, 2026 | Lalwani Nikhil | PRESIDENT & CEO | Sell | 5,400 | $71.89 | $388.2K | SEC filing |
| Oct 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $73.59 | $36.8K | SEC filing |
| Sep 29, 2026 | CAREY STEPHEN P. | SVP & CFO | Sell | 2,850 | $73.00 | $208.1K | SEC filing |
| Sep 15, 2026 | Lalwani Nikhil | PRESIDENT & CEO | Sell | 5,400 | $71.00 | $383.4K | SEC filing |
| Sep 14, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $70.79 | $35.4K | SEC filing |
| Sep 11, 2026 | Thoma Jeanne | Sell | 1,000 | $71.53 | $71.5K | SEC filing | |
| Aug 31, 2026 | CAREY STEPHEN P. | SVP & CFO | Sell | 2,850 | $72.80 | $207.5K | SEC filing |
| Aug 25, 2026 | Lalwani Nikhil | PRESIDENT & CEO | Sell | 5,400 | $74.30 | $401.2K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Aug 22, 2025 | SCHEDULE 13D/A | -22.5% (close Aug 25, 2025 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Aug 25, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Jul 27, 2026 | BlackRock, Inc. | SC 13G/A | 2,899,843 | 12.8% | Jun 30, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Nov 13, 2025 | Integrated Core Strategies (US) LLC | SC 13G/A | 53,769 | 0.2% | Sep 30, 2025 | SEC filing |
| Oct 17, 2025 | BlackRock, Inc. | SC 13G/A | 2,517,424 | 11.3% | Sep 30, 2025 | SEC filing |
| Aug 22, 2025 | Meridian Venture Partners II GP, L.P. ("GP") | SC 13D/A | 1,014,381 | 4.7% | Aug 21, 2025 | SEC filing |
| Jun 4, 2025 | Integrated Core Strategies (US) LLC | SC 13G | 1,108,127 | 5.1% | May 30, 2025 | SEC filing |
| Apr 10, 2025 | Millennium Management LLC | SC 13G/A | 818,341 | 3.8% | Mar 31, 2025 | SEC filing |
| Mar 13, 2025 | Meridian Venture Partners II GP, L.P. ("GP") | SC 13D/A | 1,164,381 | 5.4% | Mar 11, 2025 | SEC filing |
| Jan 21, 2025 | Millennium Management LLC | SC 13G | 1,091,003 | 5.2% | Jan 14, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Lobbying: 19 Lobbying Disclosure Act filings named this company as client, 2018–2022; most common issues: Medical/Disease Research/Clinical Labs (9), Health Issues (8), Pharmacy (6).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
This stock does not currently pass any tracked screen.
| Filed | Items | Source |
|---|---|---|
| Nov 16, 2026 | 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
| Nov 5, 2026 | 1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
| Nov 5, 2026 | 2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Stocks A–Z · Track Record: how the signals scored · Practice timing on ANIP
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.